Cipla Revs Up Biosimilars Engine Amid Winds Of Regulatory Change - insights.citeline.com
3 days ago • Google News
Cipla Limited (CIPLA)
NSEINR 1502.8-3.33%
Price Chart
Key Statistics
Market Cap
INR 1.26T
P/E Ratio
22.52
Revenue (TTM)
INR 274.8B
Volume
2.11M
52W High
INR 1684.05
52W Low
INR 1320.88
Dividend Yield
0.00%
Beta
0.16
Technicals
50-Day MA
1499.542
200-Day MA
1486.1718
52 Week High
1684.0507
52 Week Low
1320.8824
About CIPLA
Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. The company operat.
Employees
30313
Headquarters
Mumbai, India
CEO
Mr. Umang Vohra B.E., M.B.A.
Latest News
India's Cipla beats quarterly profit, banks on new drug launches for growth - Reuters
2025-05-13 • Google News
Cipla Sponsors NYC Lung Force Walk - American Lung Association
2025-06-30 • Google News
Environment, Social and Governance (ESG) Risk Ratings
Total ESG Risk Score
37.96
Percentile: 81.38
Environmental Risk Score
4.6
Percentile: 3
Social Risk Score
22.76
Percentile: 3
Governance Risk Score
15.61
Percentile: 3
Controversy Level
ESG data provided by Sustainalytics, Inc.
CIPLA
Category Average
2Moderate Controversy Level
NoneSevere
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg